BioSpace News Archive

The Broad Institute of MIT and Harvard and Deerfield Management announced today the advancement of two projects through their first-of-its-kind research partnership, which is aimed at solving complex, early-stage therapeutic challenges related to serious unmet medical needs.

Amneal Pharma, today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax.

Allergan today reported its fourth quarter and full-year 2017 continuing operations performance.

Helix Biopharma announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research (“AACR”) Annual Meeting 2018 which is taking place on April 14 - 18, 2018 at McCormick Place in Chicago, Illinois.

Treatment with EGFR TKIs such as erlotinib, gefitinib, or afatinib is used as first-line therapy for metastatic EGFR-mutated NSCLC.

In this newly created role, Wakefield will have overall responsibility for the company’s research services and its operational processes.

The proceeds of the offering are expected to be used primarily for the Phase 2 PISCES/KEYNOTE-695 trial in melanoma, for other clinical and research and development activities, and for working capital and general corporate purposes.

BodyNav leverages the existing on-board sensors of smartphones and advanced 3D headsets in novel and unanticipated ways to engage the body’s innate center of gravity.

CompleWare announces the release of version 2.0 of their flagship eClinical software solution, CompleClinical.

Tenax Therapeutics announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF.